Amifostine

mifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.

Amifostine

Amifostine, Ethiofos, Ethyol, Gammaphos

Amfos, Amiphos, Chemophos, Cytofos, Ethyol, M-Fost, Naprofos

({2-[(3-aminopropyl) amino] ethyl} sulfanyl) phosphonic acid

It is a cytoprotective agent and an organic thiophosphate indicates to reduce the renal toxicity associated with the administration of cisplatin repeatedly in patients with non-small cell lung cancer or advanced ovarian cancer and also used to reduce the incidence of acute to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. 

As a cytoprotective agent in chemotherapy.
Adult- initially 910 mg/m² BSA once daily, as an infusion given over 15 minutes, 30 mins beofre start of chemotherapy.

Cytoprotective agent in chemotherapy. Preventaion of Xerostomia.

Nausea, hypotension during infusion, vomiting, flushing, feeling of warmth, chills, dizziness, sneezing, cough and drowsiness, mild skin rashes.

• Amantadine  or Antihypertensives or Antidepressants  or Bromocriptine (e.g., Parlodel) or Deferoxamine (e.g., Desferal) or Pimozide (e.g., Orap) or Trimeprazine (e.g., Temaril) or Promethazine (e.g., Phenergan)
• Sometimes amifostine causes low blood pressure while it is being injected.

Caution when used during lactation and pregnancy.

Store at 20-25°C. 

Molecular weight

214.223

Molecular formula

C5H15N2O3PS

CAS number

20537-88-6

Precautions

Monitor BP every 5 min during the 15 min infusion